Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT03424473
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03379584
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT03310957
- Locations
- 🇩🇪
Marien Hospital Bottrop, Bottrop, Other, Germany
🇩🇪Klinikum der Universitat Munchen, Munchen, Other, Germany
🇰🇷Samsung Medical Center, Seoul, Other, Korea, Republic of
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
- Conditions
- Endometrium CancerEsophagus CancerLung Cancer, Nonsmall CellSquamous Cell Carcinoma of the Head and NeckOvary CancerCervix CancerProstate CancerBladder Cancer
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03245736
- Locations
- 🇬🇧
Fiona Thistlethwaite, Manchester, United Kingdom
🇬🇧Johann de Bono, Chelsea, United Kingdom
🇺🇸Brian Slomovitz, Miami, Florida, United States
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT03043313
- Locations
- 🇺🇸
Texas Oncology - Beaumont, Beaumont, Texas, United States
🇺🇸Lombardi Cancer Center / Georgetown University Medical Center, Washington, District of Columbia, United States
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Other, Spain
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02954796
- Locations
- 🇺🇸
Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
- Conditions
- Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellBreast NeoplasmsUrinary Bladder NeoplasmCarcinoma, Squamous Cell of Head and NeckColorectal NeoplasmsGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02952989
- Locations
- 🇺🇸
University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
- Conditions
- Transformed Lymphoma / DLBCLDiffuse, Large B-Cell, LymphomaFollicular Lymphoma, Grade 3b
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02855359
- Locations
- 🇵🇷
Ponce Medical School Foundation, Ponce, Puerto Rico
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02848248
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT02785900
- Locations
- 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸LSU Health Sciences Center / Feist Weiller Cancer Center, Shreveport, Louisiana, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States